Advax2
Phase 1Biologic
Advax2 is one of 10 biologic programs targeting Avian Influenza. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Avian Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPhase 3
H5N1 Pisv
NNational Institute of Allergy and Infectious Diseases (NIAID)
Approved
Tamiflu
CConrado Roberto Hoffmann Filho
Phase 2
MF59
NovartisPhase 2
A/H7N9
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
Ad4-H5-Vtn
Emergent BioSolutionsPhase 1
Recombinant Influenza Hemagglutinin
VVaxine Pty Ltd
Phase 1
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
Advax2
VVaxine Pty Ltd
Phase 1
ND1.1
VVaxart
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Advax2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- VVaxine Pty Ltd